MRNA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

633.09M

-34.46%

-2.757

-5.27%

235.15M

+117.73%

-2.340

-7.14%

125.09M

-11.91%

-2.310

+8.45%

Estimates Revision

The market is revising Downward the revenue expectations for Moderna, Inc. (MRNA) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 22.18%.

Revenue Estimates for FY2025

Revise Downward

-0.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-15.7%

In Past 3 Month

Stock Price

Go Up

+22.18%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

13 Hold

4 Sell

Hold

Current: 29.175

Low

17.00

Averages

40.13

High

198.00

Current: 29.175

Low

17.00

Averages

40.13

High

198.00

Morgan Stanley

Equal Weight

downgrade

$30 -> $28

2025-12-12

New

Reason

Morgan Stanley

Price Target

$30 -> $28

2025-12-12

New

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Moderna to $28 from $30 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

Jefferies

Hold

initiated

$30

2025-12-11

New

Reason

Jefferies

Price Target

$30

2025-12-11

New

initiated

Hold

Reason

Jefferies initiated coverage of Moderna with a Hold rating and $30 price target. For 2026, the company's Covid and RSV sales should grow ex-US with operating expense also falling about 8%, but while this is directionally helpful, Moderna will need more to meet guide, the analyst tells investors in a research note. Moderna's pipeline also needs to progress to drive non-Covid revenue to $3B, the firm added.

Piper Sandler

Overweight

NULL

downgrade

$69 -> $63

2025-11-21

Reason

Piper Sandler

Price Target

$69 -> $63

2025-11-21

downgrade

Overweight

NULL

Reason

Piper Sandler lowered the firm's price target on Moderna to $63 from $69 and keeps an Overweight rating on the shares. The firm notes Moderna laid out growth plans driven by mNEXSPIKE in 2026; mRNA-1010, intismeran and European growth in 2027; and mRNA-1083 and mRNA-1403 in 2028. Piper projects product sales of $1.73B in 2025 to grow to $2.15B in 2026.

Leerink

Underperform

maintain

$15 -> $18

2025-11-21

Reason

Leerink

Price Target

$15 -> $18

2025-11-21

maintain

Underperform

Reason

Leerink raised the firm's price target on Moderna (MRNA) to $18 from $15 and keeps an Underperform rating on the shares following the company's annual Investor Day, where it provided a commercial and pipeline update. The firm notes Moderna announced a 5-year term loan facility for up to $1.5B from Ares Management Credit Funds - with a $600M initial draw this quarter, increasing the company's FY25 cash guidance to $7.1B-$7.6B. The company reiterated FY25 revenue guidance of $1.6B-$2B revenue and FY25 GAAP operating expense guidance of $5.2B-$5.4B. Raising debt over equity makes sense to Leerink from a cost of capital perspective - though this also serves to make the company a more solvent counter-party for Roivant Sciences (ROIV) in ongoing IP litigation, given the substantial royalty award/settlement risk to Moderna, should the company be found to infringe.

RBC Capital

Luca Issi

Sector Perform

downgrade

$28 -> $25

2025-11-21

Reason

RBC Capital

Luca Issi

Price Target

$28 -> $25

2025-11-21

downgrade

Sector Perform

Reason

RBC Capital analyst Luca Issi lowered the firm's price target on Moderna to $25 from $28 and keeps a Sector Perform rating on the shares after its Analyst Day presentation. Vaccination rates are down 28% this year, but Moderna sees their top-line re-inflecting next year driven by COVID contracts ex-US and the uptake of their next-gen COVID vaccine, the analyst tells investors in a research note. RBC adds that while it appreciates all the progress and an organization that is now much more focused on managing costs, the firm remains on the sideline awaiting further clarity on top-line re-inflection.

Wolfe Research

Underperform

maintain

$16 -> $17

2025-11-20

Reason

Wolfe Research

Price Target

$16 -> $17

2025-11-20

maintain

Underperform

Reason

Wolfe Research raised the firm's price target on Moderna to $17 from $16 and keeps an Underperform rating on the shares. The firm comes away from Moderna's Analyst Day modestly more encouraged by its gross margin expansion efforts and potential revenue growth in 2026 driven by vaccine sales in U.K./CAN/AUS. Wolfe refreshes its model with the 2026-2028 guide and Ares financing.

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -3.51, compared to its 5-year average forward P/E of -1.64. For a more detailed relative valuation and DCF analysis to assess Moderna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.64

Current PE

-3.51

Overvalued PE

11.78

Undervalued PE

-15.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.94

Current EV/EBITDA

-2.18

Overvalued EV/EBITDA

7.80

Undervalued EV/EBITDA

-11.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.22

Current PS

6.01

Overvalued PS

8.96

Undervalued PS

3.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 437.15% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MRNA News & Events

Events Timeline

No data

News

4.0

12-13NASDAQ.COM

Jefferies Begins Coverage of Moderna (MRNA) with a Hold Rating

7.0

12-12Newsfilter

FDA May Add Black Box Warning to COVID Vaccines as Uptake Drops 27%

9.0

12-12Benzinga

FDA Considers Black Box Warning for COVID Vaccines Amid Expert Opposition

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 29.1755 USD — it has decreased -0.97 % in the last trading day.

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

What is the price predicton of MRNA Stock?

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 1.02B USD, decreased -45.44 % YoY.

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -0.51 USD, decreased -1800.00 % YoY.

What changes have occurred in the market's expectations for Moderna Inc (MRNA)'s fundamentals?

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 5800 emplpoyees as of December 15 2025.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 11.51B USD.